Literature DB >> 17408371

Pulmonary vaccine delivery.

Dongmei Lu1, Anthony J Hickey.   

Abstract

This review will discuss developments in the field of pulmonary vaccine delivery. The possibilities of adopting aerosol-generation technology and specific pharmaceutical formulations for the purpose of pulmonary immunization are described. Aerosol-generation systems might offer advantages with respect to vaccine stability and antigenicity. Adjuvants and their inclusion in vaccine-delivery systems are described. Other formulation components, such as surfactants, particulate systems and dispersion of the aerosols are detailed in this paper. The noninvasive, relatively safe and low-cost nature of pulmonary delivery may provide great benefits to the public health vaccination campaign.

Mesh：

Substances：

Year:  2007        PMID： 17408371     DOI： 10.1586/14760584.6.2.213

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  28 in total

1.  Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles.

Authors:  Ibrahim M El-Sherbiny; Hugh D C Smyth
Journal:  Mol Pharm       Date:  2011-12-28       Impact factor: 4.939

2.  Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses.

Authors:  Pavan Muttil; Brian Pulliam; Lucila Garcia-Contreras; John Kevin Fallon; Chenchen Wang; Anthony James Hickey; David A Edwards
Journal:  AAPS J       Date:  2010-09-28       Impact factor: 4.009

Review 3.  Pharmaceutical particle engineering via spray drying.

Authors:  Reinhard Vehring
Journal:  Pharm Res       Date:  2007-11-28       Impact factor: 4.200

4.  Immunization by a bacterial aerosol.

Authors:  Lucila Garcia-Contreras; Yun-Ling Wong; Pavan Muttil; Danielle Padilla; Jerry Sadoff; Jessica Derousse; Willem Andreas Germishuizen; Sunali Goonesekera; Katharina Elbert; Barry R Bloom; Rich Miller; P Bernard Fourie; Anthony Hickey; David Edwards
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-14       Impact factor: 11.205

5.  A nonhuman primate toxicology and immunogenicity study evaluating aerosol delivery of AERAS-402/Ad35 vaccine: Evidence for transient t cell responses in peripheral blood and robust sustained responses in the lungs.

Authors:  David A Hokey; Robert Wachholder; Patricia A Darrah; Diane L Bolton; Dan H Barouch; Krystal Hill; Veerabadran Dheenadhayalan; Stephan Schwander; C Steven Godin; Macaya Douoguih; Maria Grazia Pau; Robert A Seder; Mario Roederer; Jerald C Sadoff; Donata Sizemore
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.

Authors:  Dongmei Lu; Lucila Garcia-Contreras; Pavan Muttil; Danielle Padilla; Ding Xu; Jian Liu; Miriam Braunstein; David N McMurray; Anthony James Hickey
Journal:  AAPS J       Date:  2010-04-27       Impact factor: 4.009

7.  Transcutaneous immunization studies in mice using diphtheria toxoid-loaded vesicle formulations and a microneedle array.

Authors:  Zhi Ding; Suzanne M Bal; Stefan Romeijn; Gideon F A Kersten; Wim Jiskoot; Joke A Bouwstra
Journal:  Pharm Res       Date:  2010-03-17       Impact factor: 4.200

8.  Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles.

Authors:  Chandan Thomas; Vivek Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2010-03-16       Impact factor: 4.200

Review 9.  Technical transformation of biodefense vaccines.

Authors:  Shan Lu; Shixia Wang
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

10.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.